Table 6

Association between nonsteroidal anti-inflammatory drug (NSAID) use and breast cancer according to stage among screened women, National Institutes of Health–AARP Study

In situ breast cancer

Invasive breast cancer

NSAID use

Number of cancers

Person-years

Relative risk^a

95% confidence interval

P value for trend

Number of cancers

Person-years

Relative risk^a

95% confidence interval

P value for trend

Aspirin use^b

Never

241

192,125

1.00 (referent)

0.02

916

194,396

1.00 (referent)

0.15

<1/week

180

179,747

0.77

0.63 to 0.93

847

181,986

0.98

0.89 to 1.07

1–6/week

97

90,680

0.82

0.65 to 1.05

402

91,715

0.90

0.80 to 1.01

1+/day

96

99,793

0.75

0.59 to 0.95

476

101,064

0.95

0.85 to 1.06

Non-aspirin NSAID use^b

Never

218

209,044

1.00 (referent)

0.50

982

211,655

1.00 (referent)

0.62

<1/week

222

185,624

1.16

0.95 to 1.40

852

187,741

0.98

0.89 to 1.07

1–6/week

97

90,035

1.03

0.81 to 1.31

428

91,161

1.03

0.92 to 1.16

1+/day

76

77,462

0.89

0.69 to 1.16

384

78,439

1.02

0.91 to 1.15

This analysis was restricted to women who reported ≥2 mammograms in the past 3 years. ^aAdjusted for age (continuous), race, age at first birth, hormone therapy use, number of breast biopsies, alcohol intake, history of hypertension, and family history of breast cancer in first-degree relative. ^bThese models also include terms for frequency of use of opposite NSAID type.

Gierach et al. Breast Cancer Research 2008 10:R38   doi:10.1186/bcr2089